Evaluating the Safety Profile of Ticagrelor: Insights from Literature and Database Analysis - Top-Institutions - MDSpire

Evaluating the Safety Profile of Ticagrelor: Insights from Literature and Database Analysis

  • By

  • Renzhu Liu

  • Lu Xiao

  • Qingzi Yan

  • Xiang Liu

  • February 2, 2026

  • 0 min

Share

Top Institutions in Cardiology

Brief introduction explaining scope and methodology.

  • #1

    Brigham and Women's Hospital
    Brigham and Women's Hospital

    Boston, MA

    Key Differentiators

    • Cardiology
    • Pharmacology
    • Clinical Research

  • #2

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, OH

    Key Differentiators

    • Cardiology
    • Interventional Cardiology
    • Pharmacology

  • #3

    Mount Sinai Health System
    Mount Sinai Health System

    New York, NY

    Key Differentiators

    • Cardiology
    • Pharmacology
    • Clinical Epidemiology

  • #4

    University of Oxford
    University of Oxford

    Oxford, Oxfordshire

    Key Differentiators

    • Cardiovascular Medicine
    • Pharmacology
    • Clinical Trials

  • #5

    Stanford University Medical Center
    Stanford University Medical Center

    Stanford, CA

    Key Differentiators

    • Cardiology
    • Pharmacology
    • Clinical Research

Original Source(s)

Evaluating the Safety Profile of Ticagrelor: Insights from Literature and Database Analysis

  • by Renzhu Liu, Lu Xiao, Qingzi Yan, Xiang Liu

  • February 2, 2026

Related Content

The prognostic value of systemic inflammatory response index (SIRI) in acute coronary syndrome patients treated with primary percutaneous coronary intervention: a meta-analysis and systematic review

AMA Backs Structured Vaccine Review

Medical societies and public health groups will collaborate on policy questions and evidence briefs for the 2026 to 2027 respiratory virus season.

Flu Vaccination Linked to Lower Heart, Stroke Risk After Infection

A Danish registry study suggests prior influenza vaccination is associated with lower short-term cardiovascular risk following breakthrough infection.